Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — Q4 2024 Earnings Presentation
27 slides from Jazz Pharmaceuticals's earnings presentation, Feb 25, 2025
Slide 1: 2024 Fourth Quarter and Full Year Financial Results
February 25, 2025 2024 Fourth Quarter and Full Year Financial Results Innovating to Transform the Lives of Patients and Their Families Markella EPIDIOLEX® patient diagnosed with Dravet syndrome February 25, 2025
Slide 2: Caution Concerning Forward-Looking Statements
Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company’s growth prospects and future financial and operating results, in
Slide 3: Non-GAAP Financial Measures
Transforming Lives. Redefining Possibilities. Non-GAAP Financial Measures To supplement Jazz Pharmaceuticals’ financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP (also referred to as adjusted or non-GAAP
Slide 4: Introduction and Overview
Introduction and Overview Bruce Cozadd Chairman and Chief Executive Officer 4 February 25, 2025
Slide 5: Positioned to Drive Long-Term Shareholder Value
Positioned to Drive Long-Term Shareholder Value PIPELINE Zanidatamab and Zepzelca indication expansion opportunities; additional COMMERCIAL pipeline programs under Growing and diversified development Operational revenues expected to generate excellence and a significant cash flow disciplined, strate
Slide 6: Strong 2024 Execution and Continued Focus on Growth
Strong 2024 Execution and Continued Focus on Growth COMMERCIAL PIPELINE FINANCIAL Growing and diversified revenues generate Zanidatamab 1L GEA is a Disciplined capital allocation enables significant cash flows near-term catalyst investment in growth Sleep1: Zanidatamab: Achieved 2024 guidance: • Xyw
Slide 7: Commercial Performance
Commercial Performance Renée Galá President and Chief Operating Officer 7 February 25, 2025
Slide 8: Xywav: Differentiated by Low Sodium; IH Provides Growth Opportunity
Xywav: Differentiated by Low Sodium; IH Provides Growth Opportunity Sleep2 therapeutic area: • Total sleep2 revenue of $506 million in 4Q24; $1.9 billion in FY24 IH Narcolepsy 14,150 13,225 13,625 12,950 3,900 12,300 3,550 3,050 3,300 Xywav remains the only low-sodium oxybate therapy 2,775 • Increas
Slide 9: Epidiolex: Durable Growth; High Unmet Need in Pediatric Onset Epilepsy
Epidiolex: Durable Growth; High Unmet Need in Pediatric Onset Epilepsy 15% revenue growth in 2024 Epidiolex is the #1 branded epilepsy treatment1 $972 • Poised to reach blockbuster status in 2025 14% revenue $845 Growth opportunities: growth in 4Q24 • Continued education on synergies from treatment
Slide 10: Rely on Rylaze: Critical Component of U.S. ALL/LBL Treatment Protocols
Rely on Rylaze: Critical Component of U.S. ALL/LBL Treatment Protocols 4% revenue growth in 2024 Sustained asparaginase activity over the course of therapy essential to treatment success of ALL/LBL patients1 • Only therapy available to patients in the U.S. who have a hypersensitivity Revenues in-lin
Slide 11: Zepzelca: Opportunity to Redefine 1L SCLC Treatment Paradigm
PIPELINE Zepzelca: Opportunity to Redefine 1L SCLC Treatment Paradigm 11% revenue growth in 2024 Well-established as 2L SCLC treatment of choice Plan to submit sNDA in 1H25 for use as maintenance therapy 6% revenue in 1L ES-SCLC $320 growth in 4Q24 $290 • Reported statistically significant and clini
Slide 12: Ziihera: BTC Launch Driven by Proven Jazz Oncology Team and Infrastructure
Ziihera: BTC Launch Driven by Proven Jazz Oncology Team and Infrastructure • Proven team with deep oncology experience, including extensive expertise in the HER2 therapy Right Team, Right Capabilities space, helps drive additional adoption and uptake • Infrastructure in place for a successful Ziiher
Slide 13: Research & Development
Research & Development Robert Iannone, M.D., M.S.C.E. Executive Vice President, Global Head of Research & Development 13 February 25, 2025
Slide 14: Key Pipeline Programs
Key Pipeline Programs Key Clinical Programs PHASE 1 PHASE 2 PHASE 3 PHASE 4 / REGULATORY Recent / Upcoming Milestones 2L BTC (pivotal) Ziihera® approved in 2L BTC in 4Q24 Phase 3 1L GEA (pivotal) Phase 3 top-line PFS readout expected 2H25 Phase 3 1L BTC Phase 3 confirmatory trial in 1L BTC ongoing Z
Slide 15: Ziihera: Unique MOA Drives Compelling Clinical Profile and Patient Outcomes
Ziihera: Unique MOA Drives Compelling Clinical Profile and Patient Outcomes Unique dual-targeting Compelling and Favorable Combination data HER2 bispecific durable responses tolerability profile supports ability to antibody provides help drive improved contributes to combine with other differentiate
Slide 16: Zanidatamab: De-Risked Near-Term Opportunity with $2B+ Peak Potential
Zanidatamab: De-Risked Near-Term Opportunity with $2B+ Peak Potential Significant regulatory progress: • Ziihera now approved in the U.S. for the treatment of adults with previously treated, unresectable or metastatic HER2+ (IHC3+) BTC Other HER2-Expressing Cancers Breast Cancer Broad potential beyo
Slide 17: Financial Performance
Financial Performance Phil Johnson Executive Vice President, Chief Financial Officer 17 February 25, 2025
Slide 18: 2024 Top-Line Growth
2024 Top-Line Growth 4Q24 TOTAL REVENUES 2024 TOTAL REVENUES +8% +6% Continue to grow and diversify commercial portfolio: $4,069M $3,834M • Xywav revenues of $1,473M in 2024, $1,088M $1,111M 16% annual growth $1,012M $1,015M $292M • Epidiolex revenues of $972M in 2024,48% $274M $2,784M $2,916M 15% a
Slide 19: Disciplined Capital Allocation Drives Flexibility to Invest
Disciplined Capital Allocation Drives Flexibility to Invest 2024 NON-GAAP 2024 NON-GAAP ANI1 ADJUSTED EPS1,2 +6% +14% Disciplined capital allocation has driven: • Strong ANI1 growth in 2024 of 6% $1,092M • Significant operating cash flows $1,370M in 2024 of $1.4B $1,296M $20.90 $18.29 All while cons
Slide 20: 2025 Revenue Guidance
2025 Revenue Guidance TOTAL REVENUE Top-line growth driven by diversified portfolio +5%4 spanning sleep1, epilepsy and oncology $4,150M- $4,400M #1 treatment Standard of care in $4,069M Potential to be the in 2L ES-SCLC2; pediatric ALL/LBL patients therapy of choice in expansion opportunity in with
Slide 21: 2025 Non-GAAP Adjusted Guidance; Investing to Drive Growth
2025 Non-GAAP Adjusted Guidance; Investing to Drive Growth SG&A2 R&D2 ANI2 Non-GAAP Adjusted: 2025 Guidance1 +4%3 -8%3 +6%3 Effective tax rate2 13% - 15% Net income per $22.50 - $24.00 diluted share2 Weighted-average $1,400M- 62M - 63M $1,250M- $1,370M ordinary shares $1,227M $1,500M $1,310M $941M $
Slide 22: Closing
Closing Bruce Cozadd Chairman and Chief Executive Officer 22 February 25, 2025
Slide 23: Well-Positioned to Deliver Meaningful Shareholder Value
Well-Positioned to Deliver Meaningful Shareholder Value COMMERCIAL EXECUTION PIPELINE CATALYSTS Executing launch in 2L BTC Zanidatamab Phase 3 1L GEA top-line data expected 2H25 Reaching blockbuster status Operational Potential EU 2L BTC approval as early as 2Q25 excellence and a disciplined, strate
Slide 24: Appendix
Appendix 24 February 25, 2025
Slide 25: Glossary
Glossary Acronym Definition Acronym Definition 1L First-line HSR Hypersensitivity reaction 2024 Notes Our 1.50% exchangeable senior notes due 2024 IH Idiopathic hypersomnia 2026 Notes Our 2.000% exchangeable senior notes due 2026 IHC Immunohistochemistry 2L Second-line LGS Lennox-Gastaut Syndrome AE
Slide 26: Reconciliation of GAAP Reported Net Income, Diluted EPS, SG&A and R&D to Non-GAAP
Reconciliation of GAAP Reported Net Income, Diluted EPS, SG&A Expenses and R&D Expenses to Non-GAAP Adjusted Net Income, Diluted EPS, SG&A Expenses and R&D Expenses1 Year Ended December 31, 2024 Year Ended December 31, 2023 In thousands, except per share amounts (unaudited) Net Income Diluted EPS2 N
Slide 27: 2025 Guidance - Reconciliation of Projected GAAP to Non-GAAP Measures
2025 Guidance1 - Reconciliation of Projected GAAP Net Income, Diluted EPS, SG&A Expenses, R&D Expenses and the Effective Tax Rate to Projected Non-GAAP Adjusted Net Income, Diluted EPS, SG&A Expenses, R&D Expenses and the Effective Tax Rate 2025 Guidance1 2025 Guidance1 In millions, except per share